【摘要】：目的：子宮內(nèi)膜癌是女性生殖系統(tǒng)最常見(jiàn)的惡性腫瘤，子宮內(nèi)膜癌的發(fā)生、發(fā)展與很多因素有關(guān)，如長(zhǎng)期雌激素刺激同時(shí)無(wú)孕激素拮抗等機(jī)制。同時(shí)，他莫昔芬（tamoxifen TAM）作用后，子宮內(nèi)膜癌的發(fā)生率明顯升高。但是，目前對(duì)于TAM引起子宮內(nèi)膜癌的發(fā)病機(jī)制仍不清楚。關(guān)于染色體重組復(fù)合物的研究日益增多，具有抑制DNA合成的作用，故其突變低表達(dá)能夠促進(jìn)細(xì)胞無(wú)限分裂，進(jìn)而發(fā)展成癌。ARID1A（AT-richinteracting domain containing protein，又稱腦蛋白120、SMARCF1、p270等）是染色質(zhì)重組復(fù)合物之一，同時(shí)作為抑癌基因，在多種腫瘤組織中存在突變。目前對(duì)于ARID1A的結(jié)構(gòu)研究較多，對(duì)其在子宮內(nèi)膜癌中的表達(dá)及生物學(xué)功能的研究較少。本研究通過(guò)檢測(cè)ARID1A、ERα、ERβ、PR、P53在子宮內(nèi)膜癌細(xì)胞（高分化Ishikawa、中分化HEC-1A及低分化KLE）中的基因和蛋白的表達(dá)水平，并進(jìn)一步分析TAM及雌激素（estrogen E2）處理后子宮內(nèi)膜癌細(xì)胞中ARID1A、ERα、ERβ、PR、P53基因和蛋白的表達(dá)水平變化，探討ARID1A在子宮內(nèi)膜癌的發(fā)生、發(fā)展中的可能作用機(jī)制。 方法： 1應(yīng)用實(shí)時(shí)定量qRT-PCR法檢測(cè)正常子宮內(nèi)膜組織、子宮內(nèi)膜癌細(xì)胞株（Ishikawa、HEC-1A、KLE）中ARID1A、ERα、ERβ、PR、P53mRNA的表達(dá)水平。 2應(yīng)用實(shí)時(shí)定量qRT-PCR法檢測(cè)TAM及E2依據(jù)不同濃度及不同時(shí)間處理細(xì)胞后ARID1A、ERα、ERβ、PR、P53mRNA的表達(dá)水平。 3應(yīng)用Western-blot法檢測(cè)正常子宮內(nèi)膜組織、子宮內(nèi)膜癌細(xì)胞株（Ishikawa、HEC-1A、KLE）中BAF250a、ERα、ERβ、PR、P53蛋白的表達(dá)水平。 4應(yīng)用Western-blot法檢測(cè)TAM及E2依據(jù)不同濃度及不同時(shí)間處理細(xì)胞后BAF250a、ERα、ERβ、PR、P53蛋白的表達(dá)水平。 5應(yīng)用流式細(xì)胞學(xué)測(cè)定TAM及E2依據(jù)不同濃度及不同時(shí)間處理細(xì)胞后細(xì)胞周期變化情況。 結(jié)果： 1ARID1A、ERα、ERβ mRNA及蛋白在三種子宮內(nèi)膜癌細(xì)胞中的表達(dá)均顯著低于其在正常子宮內(nèi)膜組織中的表達(dá)，經(jīng)過(guò)TAM或E2處理后，ARID1A、ERα、ERβ mRNA及蛋白表達(dá)量隨著藥物濃度的增加而降低，隨著藥物處理時(shí)間的延長(zhǎng)而降低(P 0.05)，而PR、P53mRNA及蛋白在三種子宮內(nèi)膜癌細(xì)胞中的表達(dá)低于其在正常子宮內(nèi)膜組織中的表達(dá)，經(jīng)過(guò)TAM或E2處理后，PR、P53mRNA及蛋白表達(dá)量隨著藥物濃度的增加而增加，隨著藥物處理時(shí)間的延長(zhǎng)而增加，但均低于其在正常子宮內(nèi)膜組織中的表達(dá)(P 0.05)，呈時(shí)間-劑量依賴性。 2經(jīng)過(guò)不同濃度TAM或E2在不同時(shí)間處理三種子宮內(nèi)膜癌細(xì)胞（Ishikawa、HEC-1A、KLE）后，三種細(xì)胞均表現(xiàn)為G0/G1期縮短，S期延長(zhǎng)，且隨著藥物濃度的增高及處理時(shí)間的延長(zhǎng)，G0/G1期逐漸縮短，S期逐漸延長(zhǎng)（P0.05）。 結(jié)論： 1TAM或E2處理子宮內(nèi)膜癌細(xì)胞后ARID1A、ERα、ERβmRNA及蛋白的表達(dá)明顯低于其在未經(jīng)藥物處理子宮內(nèi)膜癌中的表達(dá)，而PR、P53mRNA及蛋白的表達(dá)明顯高于其在未經(jīng)藥物處理子宮內(nèi)膜癌中的表達(dá)。 2TAM與E2可能通過(guò)下調(diào)ARID1A的表達(dá)而引起子宮內(nèi)膜癌的發(fā)生，，而且ARID1A的下調(diào)可能與ER、P53存在一定相互作用關(guān)系。 3經(jīng)TAM與E2處理后子宮內(nèi)膜癌細(xì)胞的細(xì)胞周期均表現(xiàn)為G0/G1期縮短，S期延長(zhǎng)。
[Abstract]:Objective: Endometrial carcinoma is the most common malignant tumor of female reproductive system. The occurrence and development of endometrial carcinoma are related to many factors, such as long-term estrogen stimulation and no such mechanism as progestogen antagonism. At the same time, tamoxifen (tamoxifen) was used to increase the incidence of endometrial carcinoma. However, the pathogenesis of endometrial cancer is still unclear for TAM. The research on the chromosomal recombination complex has been increasing, and has the effect of inhibiting the DNA synthesis, so that the mutant low expression can promote the infinite division of the cell, and further develop the cancer. ARID1A (AT-ricinting domain containment protein, also known as brain protein 120, SMARCF1, p270, etc.) is one of the recombinant complexes of chromatin, and as a tumor suppressor gene, there are mutations in various tumor tissues. At present, there are many studies on the structure of ARID1A, and the study of its expression and biological function in endometrial carcinoma is less. The expression of ARID1A, ER, ER, PR, P53 in endometrial cancer cells (HEC-1A and low-differentiated KLE) and the expression levels of genes and proteins in endometrial cancer cells (HEC-1A and low-differentiated KLE) were detected and the ARID, ER, ER and ER levels in the endometrial cancer cells were further analyzed. The expression level of PR, P53 gene and protein was changed, and the possible mechanism of ARID1A in the development and development of endometrial carcinoma was discussed. square Method:1 A real-time quantitative qRT-PCR was used to detect the expression of ARID1A, ER, ER, PR, P53mRNA in normal endometrium and endometrial carcinoma (Ishikawa, HEC-1A, KLE). The levels of AID1A, ER, ER, PR, P53mRNA were detected by real-time quantitative qRT-PCR. The level of expression of BAF250a, ER, ER, PR, P53 in normal endometrial tissue, endometrial carcinoma cell (Ishikawa, HEC-1A, KLE) was detected by Western-blot. The expression level of the protein was detected by Western-blot, and then the cells were treated with different concentrations and different time. The BAF250a, ER antigen, ER antigen, PR, P were treated with different concentrations and time. The expression level of 53 protein was measured by flow cytometry. After the cell Results: The expression of ARID1A, ER, ER, ER-mRNA and protein in three endometrial cancer cells was significantly lower than that in normal endometrial tissues. The expression of PR, P53mRNA and protein in the three endometrial cancer cells decreased with the increase of the drug concentration (P 0.05). The expression of PR, P53mRNA and protein in the three endometrial cancer cells was lower than that in the normal endometrial tissues. The expression of PR, P53mRNA and protein after treatment with TAM or E2 The amount of expression increases with the increase of the drug concentration, which increases with the increase of the drug treatment time, but is lower than the expression of the drug in the normal endometrium (P 0.05) Time-dose-dependent. After treatment of three endometrial cancer cells (Ishikawa, HEC-1A, KLE) at different times through different concentrations of TAM or E2, the three cells showed a decrease in G0/ G1 phase and an extension of S phase, and the G0/ G1 phase was decreased with the increase of drug concentration and the time of treatment. gradual shortening Conclusion: The expression of ARID1A, ER, ER, ER-mRNA and protein in the endometrial carcinoma cells after treatment with 1TAM or E2 was significantly lower than that of the non-drug-treated endometrial carcinoma, while the expression of PR, P53mRNA and protein was significantly lower. significantly higher than that in endometrial cancer without drug treatment. TAM and E2 may cause endometrial cancer by down-regulation of the expression of ARID1A, and ARID1 A's down-regulation may have a certain interaction with ER and P53. After treatment with TAM and E2, the endometrium
【學(xué)位授予單位】：河北醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2014
【分類號(hào)】：R737.33

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 張倩;顏海波;劉鋒;;抑癌基因ARID1A在腫瘤中的研究進(jìn)展[J];中國(guó)細(xì)胞生物學(xué)學(xué)報(bào);2014年01期

2 侯新新;趙萌;王紅霞;張貴宇;;PPARγ ERα和ERβ在子宮內(nèi)膜癌的表達(dá)及其相關(guān)性分析[J];中國(guó)腫瘤臨床;2013年17期

3 張正茂;李霞;楊雪梅;張敏潔;肖爽;康山;單保恩;;乳腺癌患者術(shù)后口服三苯氧胺致子宮內(nèi)膜病變相關(guān)因素分析[J];腫瘤;2013年07期

4 郭曉強(qiáng);張巧霞;黃衛(wèi)人;段相林;蔡志明;;染色質(zhì)重塑因子ARID1A的腫瘤抑制作用[J];遺傳;2013年03期

5 張慧明;梁元姣;郝群;吳元赭;;雌激素受體相關(guān)受體α與雌激素受體在子宮內(nèi)膜癌組織中的表達(dá)[J];醫(yī)學(xué)研究生學(xué)報(bào);2010年02期

6 喬玉環(huán);黃珊珊;郭瑞霞;;17β-雌二醇對(duì)Ishikawa細(xì)胞增殖及P21ras、p-Erk蛋白表達(dá)的影響[J];鄭州大學(xué)學(xué)報(bào)(醫(yī)學(xué)版);2009年02期

7 曾慧敏;王丹紅;劉文賢;;PI3K/Akt通路與腫瘤治療[J];中國(guó)腫瘤生物治療雜志;2008年01期

8 王志啟;王建六;魏麗惠;趙丹;高敏;郭瑞霞;;雌激素對(duì)子宮內(nèi)膜癌細(xì)胞膜雌激素受體α調(diào)控的時(shí)效和量效關(guān)系[J];北京大學(xué)學(xué)報(bào)(醫(yī)學(xué)版);2006年05期

9 唐一帆;蔡端;;他莫昔芬誘導(dǎo)結(jié)腸癌細(xì)胞株LoVo凋亡及機(jī)制的研究[J];上海醫(yī)學(xué);2006年04期

10 陸月紅;姜瀟;陳煜;黃瓊曉;金帆;;雌激素對(duì)子宮內(nèi)膜上皮細(xì)胞ERα mRNA表達(dá)的影響及其機(jī)制探討[J];浙江醫(yī)學(xué);2006年03期

相關(guān)博士學(xué)位論文 前1條

1 李謙平;miR-16-1抑制A549細(xì)胞株生物學(xué)行為及非小細(xì)胞肺癌ARID1A基因表達(dá)的研究[D];華中科技大學(xué);2012年

相關(guān)碩士學(xué)位論文 前1條

1 王敏;三苯氧胺對(duì)人子宮內(nèi)膜癌細(xì)胞體外增殖的影響[D];天津醫(yī)科大學(xué);2007年

本文編號(hào)：2503397